Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GOVX with free AI briefings, catalyst countdowns, and dilution alerts.

GOVX · GeoVax Labs, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.2M Cash on Hand
1.6mo Cash Runway
Follow GOVX by email Get an email when GOVX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GOVX, unsubscribe in one click. Privacy

📣 What GOVX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Adenovirus-Encoding E.coli PNP Recurrent Head and Neck Cancer Phase 1/2 · NCT03754933 Completed
Combination Intervention HIV/AIDS Phase 1/2 · NCT04357821 Completed
COVID-19 Vaccine COVID-19 Infection Phase 2 · NCT04977024 Active not recruiting
Synthetic MVA-based SARS-CoV-2 Vaccine… COVID-19 Infection Phase 1/2 · NCT04639466 Completed
B63521^11 gp120 HIV Infections Phase 1 · NCT04041674 Withdrawn
GEO-D02 DNA HIV Infections Phase 1 · NCT04041674 Withdrawn
GEO-D03 DNA vaccine HIV Infections Phase 1 · NCT01571960 Completed
IHV01 Protein HIV Infections Phase 1 · NCT04041674 Withdrawn
Modified Vaccinia Ankara Virus HIV-1 Infection Phase 1 · NCT01378156 Completed

Also used in these trials (approved or third-party drugs, not GOVX's own candidates): Fludarabine Phosphate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GOVX holds $2.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $4M/quarter from operations, an estimated runway of 1.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 65 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GOVX files for a raise →

👥 Who Owns GOVX

Insiders 15% Institutions 85% Public and other holders 0%
HolderTypeShares% of sharesAs of
Armistice Capital, LLC Institution (13G, 5%+) 1,325,537 243.46% 2026-09-30
David A Dodd
President, CEO, Director · +249,800 options
Insider 36,661 6.73% 2025-04-01
John N Jr Spencer
Director · +24,050 options
Insider 21,402 3.93% 2025-10-17
Mark Reynolds
CFO · +103,300 options
Insider 14,013 2.57% 2025-03-31
John W. Sharkey
VP, Business Development · +103,300 options
Insider 6,191 1.14% 2025-04-10
Kelly T. Jr. McKee
Chief Medical Officer · +103,300 options
Insider 3,494 0.64% 2025-08-07

Share count 544,453 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full GOVX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GOVX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.